IMAZODAN
98%
- Product Code: 53472
CAS:
84243-58-3
| Molecular Weight: | 240.26 g./mol | Molecular Formula: | C₁₃H₁₂N₄O |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD00867109 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | Room temperature, sealed, dry |
Product Description:
Imazodan is primarily used in the field of cardiovascular research due to its role as a selective phosphodiesterase III inhibitor. It is studied for its potential to enhance cardiac function by increasing cyclic AMP levels, which leads to improved myocardial contractility and vasodilation. This makes it a compound of interest in the development of treatments for heart failure and other cardiac conditions. Additionally, its mechanism of action is explored in pharmacological studies to understand its effects on smooth muscle relaxation and its potential applications in managing pulmonary hypertension. Imazodan's properties are also investigated in preclinical settings to evaluate its efficacy and safety profile for therapeutic use.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | Yellow Solid |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | £11.31 |
+
-
|
| 0.250 | 10-20 days | £17.42 |
+
-
|
| 1.000 | 10-20 days | £39.49 |
+
-
|
| 5.000 | 10-20 days | £138.42 |
+
-
|
IMAZODAN
Imazodan is primarily used in the field of cardiovascular research due to its role as a selective phosphodiesterase III inhibitor. It is studied for its potential to enhance cardiac function by increasing cyclic AMP levels, which leads to improved myocardial contractility and vasodilation. This makes it a compound of interest in the development of treatments for heart failure and other cardiac conditions. Additionally, its mechanism of action is explored in pharmacological studies to understand its effects on smooth muscle relaxation and its potential applications in managing pulmonary hypertension. Imazodan's properties are also investigated in preclinical settings to evaluate its efficacy and safety profile for therapeutic use.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
£0.00
£0.00
Total :